Most recent by Manesh R. Patel, MD, FACC, FAHA, FSCAI
Baxdrostat does not meet primary endpoint for BP reduction, possibly due to nonadherence
NEW ORLEANS — Baxdrostat, an aldosterone synthase inhibitor, did not lower systolic BP compared with placebo at 8 weeks in patients with uncontrolled hypertension, but nonadherence may have been a factor, researchers reported.
Imaging data may predict best responders to evolocumab therapy: YELLOW III
NEW ORLEANS — In adults with stable CAD on maximally tolerated statin therapy, more intensive lipid lowering with evolocumab was associated with favorable coronary plaque characteristics seen on multiple CV imaging modalities, data show.
VIDEO: Takeaways from AHA 2022 with Manesh R. Patel, MD, FACC, FAHA, FSCAI
CHICAGO — In this Healio exclusive, Manesh R. Patel, MD, FACC, FAHA, FSCAI, provides his perspective on a few of the late-breaking clinical trials presented at the American Heart Association Scientific Sessions.
Pemafibrate lowers triglycerides but not CV events in type 2 diabetes, mixed dyslipidemia
CHICAGO — In the PROMINENT trial, pemafibrate lowered triglycerides but did not cut the incidence of CV events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia.
No difference in CV outcomes with two common diuretics among veterans with hypertension
CHICAGO — Among older veterans with hypertension, there was no difference in the incidence of major adverse CV events after treatment with hydrochlorothiazide compared with chlorthalidone, according to new research.
Loop diuretic choice does not reduce all-cause death in HF: TRANSFORM-HF
CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for adults hospitalized with HF, including all-cause mortality and all-cause hospitalization, researchers reported.